These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 6539524)
21. [Radiation and drug therapy of prostatic cancer]. Matveev BP; Makarova GV; Bukharkin BV Urol Nefrol (Mosk); 1986; (3):65-72. PubMed ID: 3090758 [No Abstract] [Full Text] [Related]
22. [Prostate cancer with penile metastasis: a case report]. Sawada A; Segawa T; Nakanishi S; Kinoshita H; Yamamoto S; Kamoto T; Ogawa O Hinyokika Kiyo; 2005 Nov; 51(11):771-3. PubMed ID: 16363713 [TBL] [Abstract][Full Text] [Related]
23. Chemo-endocrine therapy for prostate cancer with bone metastasis. Nagasaki Prostate Cancer Research Group. Sakai H; Minami Y; Kanetake H; Saito Y Cancer Chemother Pharmacol; 1994; 35 Suppl():S23-6. PubMed ID: 7994782 [TBL] [Abstract][Full Text] [Related]
24. Combined hormone-chemotherapy for metastatic prostatic carcinoma. Eleven-year follow-up. Servadio C; Savion M; Mukamel E Urology; 1987 Oct; 30(4):352-5. PubMed ID: 3660524 [TBL] [Abstract][Full Text] [Related]
25. [Treatment of newly diagnosed stage D2 prostatic carcinoma with hormonal therapy alone, or chemotherapy agents in combination with hormones]. Fujii A; Oka N; Miyasaki S; Higuchi A; Tomioka O; Morishita S; Yamanaka K; Itoh N; Okamoto Y; Tanaka H Nihon Hinyokika Gakkai Zasshi; 1991 Oct; 82(10):1656-63. PubMed ID: 1722834 [TBL] [Abstract][Full Text] [Related]
26. Chemotherapy principles in the treatment of prostatic cancer. Könyves I; Müntzing J; Rozencweig M Prostate; 1984; 5(1):55-62. PubMed ID: 6364076 [TBL] [Abstract][Full Text] [Related]
27. Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study. Wozniak AJ; Blumenstein BA; Crawford ED; Boileau M; Rivkin SE; Fletcher WS Cancer; 1993 Jun; 71(12):3975-8. PubMed ID: 8508363 [TBL] [Abstract][Full Text] [Related]
29. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. Amato RJ; Hernandez-McClain J; Henary H Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583 [TBL] [Abstract][Full Text] [Related]
30. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. Pienta KJ; Redman B; Hussain M; Cummings G; Esper PS; Appel C; Flaherty LE J Clin Oncol; 1994 Oct; 12(10):2005-12. PubMed ID: 7523606 [TBL] [Abstract][Full Text] [Related]
31. [Combination chemotherapy including cis-platinum in Ewing's sarcoma]. Matsumoto S; Kawaguchi N; Amino K; Manabe J; Furuya K; Isobe Y Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1913-6. PubMed ID: 3592719 [TBL] [Abstract][Full Text] [Related]
32. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Fizazi K; Sikes CR; Kim J; Yang J; Martinez LA; Olive MC; Logothetis CJ; Navone NM Anticancer Res; 2004; 24(5A):2897-903. PubMed ID: 15517894 [TBL] [Abstract][Full Text] [Related]
34. [Optimal treatment for elderly high-risk prostate cancer patients]. Soga N; Sugimura Y Gan To Kagaku Ryoho; 2007 Mar; 34(3):387-92. PubMed ID: 17353629 [TBL] [Abstract][Full Text] [Related]
35. Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Murphy GP; Huben RP; Priore R Urology; 1986 Jul; 28(1):36-40. PubMed ID: 3523938 [TBL] [Abstract][Full Text] [Related]
36. Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer. Cerulli C; Sciarra A; Salvatori G; Di Silverio F Urology; 2004 Dec; 64(6):1231.e1-3. PubMed ID: 15596212 [TBL] [Abstract][Full Text] [Related]
37. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518 [TBL] [Abstract][Full Text] [Related]
38. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. Buonerba C; Federico P; D'Aniello C; Rescigno P; Cavaliere C; Puglia L; Ferro M; Altieri V; Perdonà S; De Placido S; Di Lorenzo G Cancer Chemother Pharmacol; 2011 Jun; 67(6):1455-61. PubMed ID: 21365219 [TBL] [Abstract][Full Text] [Related]
39. Failure of chemotherapy to prolong life in patients with metastatic prostate cancer who have failed androgen deprivation. Hickey D; Cant J; Soloway MS Urology; 1988 Jan; 31(1):38-40. PubMed ID: 2447693 [TBL] [Abstract][Full Text] [Related]
40. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. Mackler NJ; Pienta KJ; Dunn RL; Cooney KA; Redman BG; Olson KB; Fardig JE; Smith DC Clin Genitourin Cancer; 2007 Jun; 5(5):318-22. PubMed ID: 17645828 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]